What constitutes meaningful benefit of cancer drugs in the context of LMICs? A mixed-methods study of oncologists’ perceptions on endpoints, benefit, price, and value of cancer drugs
Oncologists in India showed awareness of the limited surrogacy between RR/PFS and OS but assumed that RR/PFS correlated with improved quality of life and acknowledged price as a factor in deciding treatment choices. This is the first study providing a benchmark for minimum clinical benefit (4.5 months in PFS or OS) and maximum monthly price (120 USD for PFS, 360 USD for OS) deemed justifiable by oncologists practicing in low-and-middle-income countries.
Authors
- Soumitra Shankar Datta (ORCID: https://orcid.org/0000-0003-1674-5093)
- Bhawna Sirohi (ORCID: https://orcid.org/0000-0001-8093-1531)
- Bishal Gyawali (ORCID: https://orcid.org/0000-0001-7444-8594)
- Sanjit Kumar Agrawal (ORCID: https://orcid.org/0000-0002-3561-4534)
- Arnab Mukherjee (ORCID: https://orcid.org/0000-0002-6325-7116)
- Atul Sharma (ORCID: https://orcid.org/0000-0002-8960-5449)
Institutions
- Queen's University (CA)
- Tata Medical Center (IN)
- University College London (GB)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103976
- Citations
- 2
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- Ontario Institute for Cancer Research
- Government of Ontario